Study in Nature Communications finds drug DDL-920 fully reproduces physical stroke rehabilitation effects in mice by restoring gamma oscillations and parvalbumin neuron connections.
Key Takeaways
Stroke severs brain connections remote from the damage site, disrupting gamma oscillations that coordinate motor networks; successful rehab restores these rhythms in mice and humans.
DDL-920, a UCLA-developed GABAR negative allosteric modulator, excites parvalbumin interneurons to enhance gamma oscillations and produced significant movement recovery in mouse stroke models.
No drugs currently exist for stroke recovery; all clinical standard-of-care is physical rehabilitation, which most patients cannot sustain at the intensity required.
The paper identifies both the neural substrate underlying rehab’s brain effects and a specific drug target within that circuitry, two distinct scientific contributions.
Human trials are not imminent; safety and efficacy studies for DDL-920 have not yet begun.
Hacker News Comment Review
Commenters distinguished between dead neurons at the stroke core and surviving but disconnected distant neurons; UCLA’s target is the latter, not cellular regeneration, which sets realistic expectations for the mechanism.
The sex-of-subjects issue was flagged: the study used male mice only, raising translational concerns that the headline and press release do not surface.
Parallel interest in psychedelics reopening neuroplasticity critical periods emerged as a related mechanistic thread, with commenters citing published Brain journal work on the topic.
Notable Comments
@elevaet: DDL-920 is a brain-permeable GABAR NAM that inhibits PV interneurons to enhance gamma oscillations in vitro and in vivo, with structure publicly available.
@0xWTF: Notes the study used male mice only, a omission absent from the press release framing.
